Carol Addy

2.2k total citations
26 papers, 1.1k citations indexed

About

Carol Addy is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Cellular and Molecular Neuroscience. According to data from OpenAlex, Carol Addy has authored 26 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 6 papers in Endocrinology, Diabetes and Metabolism and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Carol Addy's work include Cannabis and Cannabinoid Research (6 papers), Employment and Welfare Studies (4 papers) and Healthcare Policy and Management (4 papers). Carol Addy is often cited by papers focused on Cannabis and Cannabinoid Research (6 papers), Employment and Welfare Studies (4 papers) and Healthcare Policy and Management (4 papers). Carol Addy collaborates with scholars based in United States, Japan and Australia. Carol Addy's co-authors include Christos S. Mantzoros, Alina Gavrila, Kimberly G. Brodovicz, Sotirios Tsiodras, Adolf W. Karchmer, Melvin Khee‐Shing Leow, Dimitrios Trichopoulos, Nick Dessypris, Eleni Petridou and George P. Chrousos and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Cell Metabolism.

In The Last Decade

Carol Addy

26 papers receiving 1.1k citations

Peers

Carol Addy
Arturo Fernández‐Cruz Spain
Fred T. Fiedorek United States
Seong Ho Yoo South Korea
Barry Gumbiner United States
Samantha M. Yeligar United States
Eric Snoeck Belgium
Steven J. Hurel United Kingdom
Michael Igel Germany
Malcolm A. Young United Kingdom
Rebecca L. Pollex Canada
Arturo Fernández‐Cruz Spain
Carol Addy
Citations per year, relative to Carol Addy Carol Addy (= 1×) peers Arturo Fernández‐Cruz

Countries citing papers authored by Carol Addy

Since Specialization
Citations

This map shows the geographic impact of Carol Addy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Addy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Addy more than expected).

Fields of papers citing papers by Carol Addy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Addy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Addy. The network helps show where Carol Addy may publish in the future.

Co-authorship network of co-authors of Carol Addy

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Addy. A scholar is included among the top collaborators of Carol Addy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Addy. Carol Addy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sherman, Bruce W. & Carol Addy. (2018). Low-Wage Workers and Health Benefits Use: Are We Missing an Opportunity?. Population Health Management. 21(6). 435–437. 2 indexed citations
2.
Chen, Ya-Ting, et al.. (2018). High intensity lifestyle intervention and long-term impact on weight and clinical outcomes. PLoS ONE. 13(4). e0195794–e0195794. 6 indexed citations
3.
Sherman, Bruce W. & Carol Addy. (2018). Value-based health insurance design: how much does socioeconomic status matter?. PubMed. 24(7). 318–321. 2 indexed citations
4.
Kim, Chai-Wan, Carol Addy, Jun Kusunoki, et al.. (2017). Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metabolism. 26(2). 394–406.e6. 314 indexed citations
5.
Sherman, Bruce W. & Carol Addy. (2017). Association of Wage With Employee Participation in Health Assessments and Biometric Screening. American Journal of Health Promotion. 32(2). 440–445. 14 indexed citations
6.
Sherman, Bruce W., Teresa B. Gibson, Wendy D. Lynch, & Carol Addy. (2017). Health Care Use And Spending Patterns Vary By Wage Level In Employer-Sponsored Plans. Health Affairs. 36(2). 250–257. 26 indexed citations
7.
Sherman, Bruce W., Wendy D. Lynch, & Carol Addy. (2016). Lost in translation: healthcare utilization by low-income workers receiving employer-sponsored health insurance.. PubMed. 22(4). 286–90. 2 indexed citations
8.
9.
Addy, Carol, Daniel Tatosian, Isaias Noel Gendrano, et al.. (2016). Effects of Age, Sex, and Obesity on the Single‐Dose Pharmacokinetics of Omarigliptin in Healthy Subjects. Clinical Pharmacology in Drug Development. 5(5). 374–382. 7 indexed citations
10.
Friedman, Evan, Carol Addy, Daniel Tatosian, et al.. (2016). Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once‐weekly dipeptidyl peptidase‐4 inhibitor, in healthy Japanese men. Journal of Diabetes Investigation. 8(1). 84–92. 21 indexed citations
11.
Schoedel, Kerri A., Carol Addy, Bijan Chakraborty, et al.. (2012). Human Abuse Potential and Cognitive Effects of Taranabant, a Cannabinoid 1 Receptor Inverse Agonist. Journal of Clinical Psychopharmacology. 32(4). 492–502. 11 indexed citations
12.
Li, Xiujiang, Jace Nielsen, Brenda Cirincione, et al.. (2010). Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist. The AAPS Journal. 12(4). 537–547. 5 indexed citations
13.
Addy, Carol, C. Assaid, David Hreniuk, et al.. (2009). Single‐Dose Administration of MK‐0657, an NR2B‐Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease. The Journal of Clinical Pharmacology. 49(7). 856–864. 51 indexed citations
14.
Addy, Carol, Patricia Jumes, Hankun Li, et al.. (2009). Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist. The Journal of Clinical Pharmacology. 49(10). 1228–1238. 5 indexed citations
15.
16.
Schwartz, Jules I., Stephanie Dunbar, Jinyu Yuan, et al.. (2008). Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin. Advances in Therapy. 25(11). 1175–1190. 2 indexed citations
17.
Lepeleire, Inge De, Carol Addy, Paul Rothenberg, et al.. (2007). Brain CB-1 receptor occupancy of taranabant in lean subjects using CB-1R PET. Diabetologia. 50. 1 indexed citations
18.
Erondu, Ngozi, Carol Addy, Kaifeng Lu, et al.. (2007). NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity. 15(8). 2027–2042. 23 indexed citations
19.
Leow, Melvin Khee‐Shing, Carol Addy, & Christos S. Mantzoros. (2003). Human Immunodeficiency Virus/Highly Active Antiretroviral Therapy-Associated Metabolic Syndrome: Clinical Presentation, Pathophysiology, and Therapeutic Strategies. The Journal of Clinical Endocrinology & Metabolism. 88(5). 1961–1976. 88 indexed citations
20.
Addy, Carol, Alina Gavrila, Sotirios Tsiodras, et al.. (2003). Hypoadiponectinemia Is Associated with Insulin Resistance, Hypertriglyceridemia, and Fat Redistribution in Human Immunodeficiency Virus-Infected Patients Treated with Highly Active Antiretroviral Therapy. The Journal of Clinical Endocrinology & Metabolism. 88(2). 627–636. 177 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Arturo Fernández‐Cruz Breakdown of academic impact, for papers by Fred T. Fiedorek Breakdown of academic impact, for papers by Seong Ho Yoo Breakdown of academic impact, for papers by Barry Gumbiner Breakdown of academic impact, for papers by Samantha M. Yeligar Breakdown of academic impact, for papers by Eric Snoeck Breakdown of academic impact, for papers by Steven J. Hurel Breakdown of academic impact, for papers by Michael Igel Breakdown of academic impact, for papers by Malcolm A. Young Breakdown of academic impact, for papers by Rebecca L. Pollex
Rankless by CCL
2026